Radiation oncology and medical physicists quality assurance in British Columbia Cancer Agency Provincial Prostate Brachytherapy Program

Keyes, Mira; Morris, William; Spadinger, Ingrid; Araujo, Cynthia; Cheung, Arthur; Chng, Nick; Crook, Juanita; Halperin, Ross; Lapointe, Vince; Miller, Stacy; Pai, Howard; Pickles, Tom

doi:10.1016/j.brachy.2012.03.006

Cited by 28 publications

(19 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The PSA control curves only divide after 3 years of follow-up as the use of neoadjuvant hormone manipulation masks the impact of radiation dose on PSA control in the initial years. The British Colombia group provide an excellent example with a rigorous QA program and excellent implant quality across the province and multiple operators [13]. In over 2000 patients a median D90 of 150Gy is achieved with few low dose implants and excellent clinical outcomes.…”

Section: Discussionmentioning

confidence: 99%

The Effect of Dose and Quality Assurance in Early Prostate Cancer Treated with Low Dose Rate Brachytherapy as Monotherapy

et al. 2015

View full text Add to dashboard Cite

Aims To examine the relationship between post-implant CT dosimetry and long term PSA relapse free survival in patients treated with Iodine 125 LDR prostate brachytherapy as monotherapy and secondly, to audit recent practice against RCR guidelines following the re-introduction of post-implant dosimetry for all patients in our centre. Similarly an increase in the mean (SD) V100 from 92 (4.4) % to 95 (3.2) % is noted over time. No difference between clinicians was noted. Henry et al. 3 Conclusion D90 values of less than 140Gy continue to be predictive of increased risk of recurrence of prostate cancer across risk groups with longer follow-up. Quality assurance can be used to ensure improved and consistent implant quality in a team with multiple clinicians. Methods and Materials

show abstract

Section: Discussionmentioning

confidence: 99%

The Effect of Dose and Quality Assurance in Early Prostate Cancer Treated with Low Dose Rate Brachytherapy as Monotherapy

et al. 2015

View full text Add to dashboard Cite

show abstract

“…75 or D 90 ! 80% (14). For CTV dosimetry, there are no guidelines to stratify implant quality (6), and we used the same prostate metrics to stratify CTV to good, suboptimal, or poor implants.…”

Section: Ctv Dose Coveragementioning

confidence: 99%

“…1de1f). We used the British Columbia Cancer Agency criteria for evaluation of prostate dosimetry (14). Good prostate implants were defined as those having V 100 O 85% and D 90 O 90%, suboptimal implants were defined as those with V 100 of 75e85%, or D 90 80e90%, whereas poor implants were defined as those with V 100 !…”

Section: Ctv Dose Coveragementioning

confidence: 99%

Dosimetric evaluation of clinical target volume in the postimplant analysis of low-dose-rate brachytherapy for prostate cancer

et al. 2015

View full text Add to dashboard Cite

“…As with radical prostatectomy, 44,45 it is critical for brachytherapists to maintain a minimum volume of cases annually to maintain their skill-set. 46 It takes about 1 year of fellowship training to practice independently with competence. Unlike with surgery, training is available in only a few centres in Canada.…”

Section: Discussionmentioning

confidence: 99%

Canadian Prostate Brachytherapy in 2012

Keyes

Crook

Morris

et al. 2013

CUAJ

Self Cite

View full text Add to dashboard Cite

Prostate brachytherapy can be used as a monotherapy for low-and intermediate-risk patients or in combination with external beam radiation therapy (EBRT) as a form of dose escalation for selected intermediate-and high-risk patients. Prostate brachytherapy with either permanent implants (low dose rate [LDR]) or temporary implants (high dose rate [HDR]) is emerging as the most effective radiation treatment for prostate cancer. Several large Canadian brachytherapy programs were established in the mid-to late-1990s. Prostate brachytherapy is offered in British Columbia, Alberta, Manitoba, Ontario, Quebec and New Brunswick. We anticipate the need for brachytherapy services in Canada will significantly increase in the near future. In this review, we summarize brachytherapy programs across Canada, contemporary eligibility criteria for the procedure, toxicity and prostate-specific antigen recurrence free survival (PRFS), as published from Canadian institutions for both LDR and HDR brachytherapy.

show abstract

Radiation oncology and medical physicists quality assurance in British Columbia Cancer Agency Provincial Prostate Brachytherapy Program

Cited by 28 publications

References 29 publications

The Effect of Dose and Quality Assurance in Early Prostate Cancer Treated with Low Dose Rate Brachytherapy as Monotherapy

The Effect of Dose and Quality Assurance in Early Prostate Cancer Treated with Low Dose Rate Brachytherapy as Monotherapy

Dosimetric evaluation of clinical target volume in the postimplant analysis of low-dose-rate brachytherapy for prostate cancer

Canadian Prostate Brachytherapy in 2012

Contact Info

Product

Resources

About